Rich Stuart
Known title: Chief Medical OfficerCIK: 0001841785
Rich Stuart's purchase track record
Rich Stuart has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2025 | TENX | $96K | +26.8% | +21.5% | +11.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TENX | ▲ Buy | Open Market | 2,500 | $26K | 12/9/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 2,500 | $25K | 12/8/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 2,500 | $23K | 12/4/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 1,500 | $14K | 12/3/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 1,000 | $9K | 12/2/2025 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 9/21/2022 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 9/21/2022 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 11/29/2021 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 11/29/2021 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 10/12/2021 | View on chart |
| TENX | ▼ Sell | Gift | 1,909,585 | $0 | 10/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.